Abstract

STERIS plc is scheduled to report its fiscal fourth-quarter results on May 11, 2026 Post Market; this preview compiles the most recent quarterly actuals and current-quarter forecasts, highlights the revenue and EPS trajectory, and outlines what investors should watch across Healthcare, Applied Sterilization Technologies, and Life Sciences.

Market Forecast

Market expectations for the fiscal fourth quarter point to revenue of US dollars 1.59 billion, up 8.55% year over year, with adjusted EPS around 2.85, up 9.78% year over year; EBIT is projected at US dollars 385.77 million, up 9.19% year over year. Forecasts for gross margin and net margin are not indicated in the collected dataset.

Within the company’s main businesses, recent run-rate contributions show Healthcare as the largest revenue driver with US dollars 1.06 billion in the latest reported quarter, supported by solid demand across procedural and service categories and continued normalization of activity levels. The most promising near-term vector appears to be Applied Sterilization Technologies at US dollars 286.60 million last quarter; segment-level year-over-year growth was not disclosed alongside the dataset used in this preview, but management and analysts have been framing expectations around sustained companywide mid- to high-single-digit growth.

Last Quarter Review

In the prior reported quarter (fiscal Q3), STERIS plc delivered revenue of US dollars 1.50 billion (up 9.17% year over year), a gross profit margin of 43.79%, GAAP net income attributable to shareholders of US dollars 193.00 million with a 12.89% net profit margin, and adjusted EPS of 2.53 (up 9.05% year over year). Revenue exceeded consensus by US dollars 15.30 million while adjusted EPS tracked in line with expectations, illustrating continued top-line momentum and disciplined execution.

By business line, Healthcare contributed US dollars 1.06 billion, Applied Sterilization Technologies delivered US dollars 286.60 million, and Life Sciences posted US dollars 145.80 million, reflecting broad-based strength aligned with the 9.17% year-over-year increase at the consolidated level.

Current Quarter Outlook

Main business: Healthcare revenue scale and margin conversion

Healthcare remains the largest revenue contributor, with the latest quarter’s allocation at US dollars 1.06 billion. For the fiscal fourth quarter, the key watch point is revenue conversion to margin against the fiscal Q3 gross margin benchmark of 43.79%. Mix within Healthcare often spans higher-margin consumables and service lines alongside lower-margin capital equipment; the balance between these streams can shift the consolidated margin profile in a given quarter. A sustained cadence in consumables and service activity would typically support gross margin resiliency, whereas a heavier tilt to large equipment placements can moderate the rate of margin expansion even as revenue grows. Investors should also pay attention to order-to-revenue conversion timing and installation cycles, as elongated installation intervals can defer revenue recognition from capital equipment and pull more weight to services, influencing both growth pacing and gross margin in the near term.

Pricing discipline and procurement efficiency are incremental levers to monitor. The company’s recent performance suggests that price and productivity have been offsetting normal cost inflation, and the extent of further efficiency gains could factor into EBIT progression, with the current-quarter EBIT forecast at US dollars 385.77 million, up 9.19% year over year. Supply chain stability remains relevant for capital equipment deliveries and parts availability; steady component flow supports on-time installs and limits expedited cost headwinds that can pressure gross margin.

Most promising business: Applied Sterilization Technologies momentum and visibility

Applied Sterilization Technologies delivered US dollars 286.60 million in the previous quarter and is positioned as a potential growth vector in the current quarter’s setup. The framework for this segment often centers on recurring service revenue, asset utilization, and contractual volumes. Stability in throughput and a balanced pricing environment can underpin revenue quality and predictability, which is valuable for quarterly forecasting. While segment-level year-over-year growth rates were not provided in the dataset, the companywide revenue estimate indicates an 8.55% increase year over year, and a healthy contribution from sterilization services would support this consolidated trajectory.

From a profitability standpoint, throughput efficiency and mix across service modalities can influence margin conversion in this line. Incremental capacity additions or productivity enhancements can provide modest operating leverage when volume trends remain constructive. Investors should watch for commentary on capacity, service lead times, and contract renewals, as these operational details can color the near-term growth pace and help explain any outperformance or underperformance relative to the revenue estimate of US dollars 1.59 billion.

Key stock-price swing factors this quarter

The most immediate swing factor is whether revenue tracks at or above the US dollars 1.59 billion mark and whether the EPS outcome aligns with the 2.85 expectation, given that the prior quarter’s adjusted EPS was 2.53 and the implied year-over-year growth this quarter stands at 9.78%. Upside or downside versus this bar can be driven by mix: a greater share of higher-margin consumables and services within Healthcare and solid sterilization volumes would be supportive of gross margin, while heavier capital equipment shipment timing could weigh on margin optics despite top-line strength. Investors should also parse any updates on cost trajectory and operational efficiencies, as these influence EBIT delivery against the US dollars 385.77 million forecast, and help gauge how much of revenue growth flows through to operating income.

Another swing factor is the cadence of orders and backlog conversion through the quarter-end cut-off. Even minor delays in installations or customer acceptance milestones can move revenue from the fiscal fourth quarter into the subsequent period, altering quarter-on-quarter comparisons and shaping how guidance frames the first quarter of the next fiscal year. Finally, any updates to the full-year framework can recalibrate the near-term outlook; earlier in the fiscal year, management maintained an adjusted EPS range for the year, and any tightening or revision could affect sentiment around the quarter’s print and the subsequent glide path.

Analyst Opinions

Bullish views dominate among recently compiled sell-side and aggregated assessments, with a consensus tilt toward overweight ratings and a mean price framework that implies confidence in continued revenue and EPS progression. The prevailing bull case emphasizes consistent mid- to high-single-digit revenue expansion supported by balanced contributions from Healthcare and Applied Sterilization Technologies, alongside disciplined cost control that maintains healthy gross-to-operating margin conversion. Analysts also highlight that the company maintained its full-year adjusted EPS framework earlier in the fiscal year, signaling confidence in demand visibility and execution, which bolsters the constructive stance heading into fiscal Q4.

One widely referenced aggregation shows the average rating at overweight with a mean target in the high two-hundreds, reflecting the view that current-quarter expectations—revenue of approximately US dollars 1.59 billion and adjusted EPS around 2.85—are attainable within the existing demand and operating backdrop. The bullish perspective posits that upside could materialize if the revenue mix skews toward higher-margin consumables and services, or if sterilization volumes deliver incremental operating leverage in Applied Sterilization Technologies. In that scenario, modest outperformance on EBIT relative to the US dollars 385.77 million mark could translate into an EPS outcome that modestly exceeds the 2.85 benchmark, supporting constructive revisions to outer-quarter models.

The supportive setup further leans on recent quarterly execution evidence: the preceding quarter delivered a revenue beat of US dollars 15.30 million against consensus and adjusted EPS in line with expectations, paired with a 9.17% year-over-year revenue increase and a 9.05% uplift in adjusted EPS. Bulls argue that this pattern of steady, repeatable results raises confidence in the current quarter’s forecasts and the sustainability of the consolidated growth profile. They also note that a stable gross margin base of 43.79% last quarter, together with a 12.89% net margin, provides headroom for operating performance to track forecasts without requiring unusually favorable mix.

On balance, the majority view expects STERIS plc to meet or slightly exceed fiscal fourth-quarter consensus, underpinned by durable demand in Healthcare, solid sterilization service throughput, and unchanged cost discipline. The forward-looking discussion will likely center on the translation of fourth-quarter run rates into the initial outlook for the next fiscal year, with bulls looking for indications that revenue growth can remain in the mid- to high-single-digit range and that operational efficiencies can preserve the earnings growth algorithm near or slightly above revenue growth. If commentary around order intake, installation timing, and service productivity remains constructive, the bullish camp anticipates that sentiment will remain favorable following the Post Market release on May 11, 2026.